Discover Biotech Webinar Pharma FDA & EMA ONCOLife Contact

ONCOLife

Real-World Analysis Links Community Oncology Care to Markedly Longer Survival in Breast and Lung Cancer

ONCOLife

Early CAR T-Cell Intervention Shows Disease-Eradication Potential in High-Risk Smoldering Myeloma

ONCOLife

Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC

FDA & EMA

FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma

ONCOLife

Daraxonrasib Doubles Overall Survival in Previously Treated Metastatic Pancreatic Cancer

FDA & EMA

FDA Grants Priority Review to Ifinatamab Deruxtecan in Pretreated ES-SC Lung Cancer

ONCOLife

New Strategy Blocks NMD, Unmasks Hidden Tumor Antigens, and Boosts Immunotherapy

ONCOLife

Blocking DHODH Helps Triple Combination Overcome Resistance in Lung Cancer

ONCOLife Issues

Featured Articles

Dual Pathway Blockade Achieves 40% Response in Recurrent Clear Cell Gynaecological Cancer

26 April 2026

The Phase 2 LARA trial reported encouraging activity for pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma, achieving a 40% objective response rate within 24 weeks and a median progression-free survival of 6.4 months....

Trending Articles

AI Predicts Chemotherapy Benefit in Breast Cancer Using Routine Pathology Slides

FDA Approves Agilent’s PD-L1 Test to Guide KEYTRUDA Use in Esophageal and GEJ Carcinoma

FDA & EMA

28 March 2026

Light-Activated Copper Nanoparticles Trigger Cuproptosis in Drug-Resistant Cancer Cells

ONCOLife

27 March 2026

New Protein Modification Linked to IDH-Mutant Cancers Opens Therapeutic Possibilities

ONCOLife

26 March 2026

BioNTech Showcases Promising Bispecific and ADC Data in Lung Cancer at ELCC 2026

ONCOLife

25 March 2026

Sunvozertinib Outperforms Chemo in First-Line EGFR Exon 20 Insertion NSC Lung Cancer

Magnetic Nanoparticle-Guided Hyperthermia Opens a New Path for Advanced Solid Tumors

ONCOLife

23 March 2026

TG Therapeutics Secures $500M to Advance BRIUMVI in Relapsing Multiple Sclerosis

Biotech

20 March 2026

Targeted Bladder Cancer Therapy Erda-iDRS Achieves 89% Response Rate and PDC

ONCOLife

15 March 2026

Atirmociclib Reduces Progression Risk by 40% in CDK4/6 Metastatic Breast Cancer

ONCOLife

17 March 2026

TALAPRO-3 Trial Supports Early Use of Talazoparib in HRR+ mCS Prostate Cancer

FDA Approves Nivolumab-AVD as First Immunotherapy Combination for Hodgkin Lymphoma

FDA & EMA

20 March 2026

Abenacianine Enters Phase 3 to Enhance Real-Time Tumor Detection in Lung Surgery

ONCOLife

19 March 2026

CellCarta Secures Global Exclusivity for Aspyre Lung to Advance Lung Cancer Testing

Cancer

18 March 2026

Reengineering CAR-T Cells to Last Longer in the Fight Against Cancer and HIV

ONCOLife

15 March 2026